Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18661339 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | May 2024 | October 2024 | Abandon | 5 | 1 | 0 | No | No |
| 18408093 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | January 2024 | December 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18482628 | Compositions and Methods for Treatment of Ocular Disease Associated with Angiogenesis | October 2023 | December 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18481393 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | October 2023 | November 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18464200 | CIRCULAR RNAS AND PREPARATION METHODS THEREOF | September 2023 | October 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18362698 | RNA EDITING VIA RECRUITMENT OF SPLICEOSOME COMPONENTS | July 2023 | September 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18224017 | TREATMENTS FOR OCULAR SURFACE DISORDERS | July 2023 | February 2026 | Allow | 31 | 3 | 1 | Yes | Yes |
| 18296596 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | April 2023 | October 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18186943 | METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASES | March 2023 | January 2025 | Abandon | 22 | 3 | 0 | Yes | No |
| 18177446 | POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEIN | March 2023 | January 2026 | Allow | 34 | 2 | 1 | No | No |
| 18041613 | PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERS | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18167614 | ENGINEERED OXALATE DECARBOXYLASES | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18159161 | METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASE | January 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18145784 | VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A | December 2022 | October 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18082654 | OLIGONUCLEOTIDES FOR MLH1 MODULATION | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18078031 | SIGNAL BOOST CASCADE ASSAY | December 2022 | September 2024 | Abandon | 21 | 4 | 1 | Yes | No |
| 18063582 | NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODS | December 2022 | February 2026 | Abandon | 38 | 3 | 1 | No | Yes |
| 18058000 | PARTICLE-BASED ISOLATION OF PROTEINS AND OTHER ANALYTES | November 2022 | January 2026 | Allow | 49 | 2 | 1 | Yes | Yes |
| 17926678 | VLP FOR THE TREATMENT OF LEUKODYSTROPHIES | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17989941 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | November 2022 | January 2026 | Abandon | 38 | 1 | 1 | No | No |
| 17926564 | METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17998371 | COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17984846 | TRANS-SPLICING RNA (tsRNA) | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17978030 | METHODS OF DOSING CIRCULAR POLYRIBONUCLEOTIDES | October 2022 | February 2024 | Abandon | 16 | 2 | 0 | Yes | No |
| 17906175 | DIAGNOSTIC METHODS USING SIRT1 EXPRESSION | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17822854 | Nucleic Acid Compounds for Binding to Complement Component 3 Protein | August 2022 | June 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17883452 | METHODS FOR TREATING PATIENTS HAVING SINUSOIDAL OBSTRUCTION SYNDROME | August 2022 | July 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17814860 | PLATELETS TRANSFECTED BY EXOGENOUS GENETIC MATERIAL AND PLATELET MICROPARTICLES OBTAINED BY SAID TRANSFECTED PLATELETS, METHOD FOR THE PREPARATION AND USES THEREOF | August 2022 | March 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17814845 | PLATELETS TRANSFECTED BY EXOGENOUS GENETIC MATERIAL AND PLATELET MICROPARTICLES OBTAINED BY SAID TRANSFECTED PLATELETS, METHOD FOR THE PREPARATION AND USES THEREOF | July 2022 | February 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17814647 | Compositions for treatment of polycystic kidney disease | July 2022 | May 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17814781 | METHODS AND MEANS FOR EFFICIENT DKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-MRNA | July 2022 | March 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17814328 | METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | July 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17843848 | TARGETING MICRORNA FOR CANCER TREATMENT | June 2022 | July 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17841185 | PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | June 2022 | February 2025 | Allow | 32 | 1 | 0 | No | No |
| 17805402 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | June 2022 | February 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17826946 | Use of Thermostable RNA Polymerases to Produce RNAs Having Reduced Immunogenicity | May 2022 | August 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17825384 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER | May 2022 | August 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17778380 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17726068 | COMPOSITIONS AND METHODS FOR EDITING THE ANGIOPOIETIN-LIKE 4 (ANGPTL4) GENE | April 2022 | December 2025 | Abandon | 44 | 2 | 1 | No | Yes |
| 17708799 | COMPOSITIONS AND METHODS FOR TREATING SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD) | March 2022 | March 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17765116 | TREATMENT OF SPINAL AND BULBAR MUSCULAR ATROPHY | March 2022 | February 2025 | Allow | 35 | 3 | 1 | No | No |
| 17763662 | METHOD FOR TREATING MOOD DISORDERS | March 2022 | December 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17703334 | Compositions and Methods for MYC Messenger RNA Inhibitors | March 2022 | August 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17698829 | CORONAVIRUS VACCINE | March 2022 | July 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17696808 | Combination Therapy for Treating Disorders of the Ear | March 2022 | January 2026 | Abandon | 46 | 2 | 1 | No | No |
| 17591133 | HETERO DOUBLE-STRANDED antimiR | February 2022 | February 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17626324 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | January 2022 | September 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17571893 | RNA FOR CANCER THERAPY | January 2022 | December 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17563686 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING VIRAL INFECTIONS | December 2021 | November 2023 | Abandon | 23 | 2 | 1 | No | No |
| 17618776 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | December 2021 | June 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17549098 | SPLICE MODULATING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | December 2021 | December 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17547791 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF | December 2021 | March 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17547232 | PREDICTIVE METHOD FOR ASSESSING THE SUCCESS OF EMBRYO IMPLANTATION | December 2021 | July 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17524876 | MEANS AND METHODS FOR REDUCING TUMORIGENICITY OF CANCER STEM CELLS | November 2021 | April 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17610050 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME | November 2021 | February 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17518704 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID ANALYSIS | November 2021 | May 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17516543 | COMBINATION THERAPY | November 2021 | August 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17507669 | ANDROGEN RECEPTOR NUCLEIC ACIDS AND USES THEREOF | October 2021 | January 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17506327 | METHODS FOR IMPROVING HUMAN EGG QUALITY USING MICRORNAs | October 2021 | June 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17481670 | U1 snRNP Regulates Gene Expression and Modulates Oncogenicity | September 2021 | September 2025 | Allow | 48 | 4 | 0 | No | No |
| 17477327 | METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS | September 2021 | September 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17438903 | OLIGONUCLEOTIDE HAVING ANTI-INFLAMMATORY ACTIVITY | September 2021 | November 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17405199 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | August 2021 | April 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17401389 | Aptamers Against Clostridium Difficile | August 2021 | June 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17397652 | MODULATION OF TRANSTHYRETIN EXPRESSION | August 2021 | August 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17391125 | METHODS OF TREATING MOTOR NEURON DISEASES | August 2021 | May 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17389878 | Anti-Fibrinogen Aptamers | July 2021 | January 2025 | Allow | 41 | 2 | 1 | No | No |
| 17386127 | Method of Treating Hepatic Steatosis | July 2021 | April 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17385767 | METHOD FOR DIAGNOSIS AND PROGNOSIS OF CHRONIC HEART FAILURE | July 2021 | February 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17371765 | METHOD FOR PREVENTING ORAL CANCER | July 2021 | September 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17350004 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | June 2021 | March 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17346369 | METHODS AND COMPOSITIONS FOR TREATMENT OF FRONTOTEMPORAL DEMENTIA | June 2021 | October 2023 | Abandon | 28 | 2 | 1 | No | No |
| 17342112 | BIOMARKERS FOR EARLY EMBRYONIC VIABILITY AND METHODS THEREOF | June 2021 | September 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17336112 | METHOD FOR SCREENING APTAMER BY USING MICROARRAY MICROFLUIDIC CHIP | June 2021 | October 2025 | Abandon | 53 | 0 | 1 | No | No |
| 17331012 | UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC RNA | May 2021 | March 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17292075 | METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A) | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17307350 | SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES | May 2021 | July 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17289953 | Genome Editing by Guided Endonuclease and Single-stranded Oligonucleotide | April 2021 | April 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17241001 | COMBINATION THERAPIES FOR INNER EAR SENSORY HAIR CELL REGENERATION/REPLACEMENT | April 2021 | October 2025 | Abandon | 54 | 3 | 0 | Yes | Yes |
| 17234541 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | April 2021 | January 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17231896 | SPHERICAL NUCLEIC ACID TLR9 AGONISTS | April 2021 | January 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17228994 | Aptamers Against Clostridium Difficile | April 2021 | April 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17284556 | Nucleic Acid Compounds for Binding Immunoglobulin G | April 2021 | September 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17283941 | tRNA-DERIVED FRAGMENTS AS BIOMARKERS FOR PARKINSON'S DISEASE | April 2021 | May 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17225823 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | April 2021 | November 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17221457 | SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS | April 2021 | December 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17183205 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | February 2021 | November 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17163168 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION of NF-kB PATHWAYS AND/OR IRF PATHWAYS | January 2021 | December 2024 | Abandon | 47 | 3 | 1 | No | No |
| 17157565 | METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERS | January 2021 | October 2024 | Allow | 45 | 3 | 1 | No | No |
| 17157131 | Methods of Manipulating the Fate of Cells | January 2021 | November 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17154280 | KIT FOR AFLATOXIN B1 (AFB1) MONITORING | January 2021 | August 2023 | Allow | 31 | 2 | 0 | No | No |
| 17154325 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | January 2021 | October 2024 | Allow | 45 | 2 | 2 | No | No |
| 17153067 | AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | January 2021 | September 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17153215 | AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | January 2021 | September 2023 | Allow | 32 | 0 | 1 | No | No |
| 17130716 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | December 2020 | November 2023 | Allow | 34 | 2 | 0 | No | No |
| 17129761 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | April 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17129117 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53 | December 2020 | October 2024 | Abandon | 46 | 2 | 0 | No | Yes |
| 17129311 | METHODS FOR IDENTIFYING THERAPEUTIC AGENTS WHICH INTERACT WITH STK24 | December 2020 | June 2025 | Abandon | 53 | 4 | 1 | Yes | No |
| 17127866 | COMPOUNDS AND METHODS FOR MODULATION OF SMN2 | December 2020 | November 2022 | Abandon | 23 | 0 | 1 | No | No |
| 17251558 | PHARMACEUTICAL COMPOSITION COMPRISING FUSION PROTEIN OF CELL-PENETRATING PEPTIDE AND RPE65 FOR TREATMENT OF LEBER'S CONGENITAL AMAUROSIS | December 2020 | May 2024 | Abandon | 41 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIN, DANA H.
With a 30.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHIN, DANA H works in Art Unit 1635 and has examined 925 patent applications in our dataset. With an allowance rate of 23.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner SHIN, DANA H's allowance rate of 23.0% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHIN, DANA H receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SHIN, DANA H is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +35.9% benefit to allowance rate for applications examined by SHIN, DANA H. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.2% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 31.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 32% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 62.3% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 71.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 90.6% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.